Search Results - "Arés, Luis"

Lung cancer: current therapies and new targeted treatments by Hirsch, Fred R, Prof, Scagliotti, Giorgio V, Prof, Mulshine, James L, Prof, Kwon, Regina, BA, Curran, Walter J, Prof, Wu, Yi-Long, Prof, Paz-Ares, Luis, Prof

“…Summary Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6…”
Get full text

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options by Zugazagoitia, Jon, Paz-Ares, Luis

“…Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of…”
Get full text

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials by Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin, Pietanza, M. Catherine, Piperdi, Bilal, Gadgeel, Shirish M.

“…Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously…”
Get full text

Inhibition of HSP90 molecular chaperones: moving into the clinic by Garcia-Carbonero, Rocio, MD, Carnero, Amancio, PhD, Paz-Ares, Luis, Dr

“…Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is crucial for the stability and function of many proteins essential for cell survival…”
Get full text

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial by Paz-Ares, Luis G, Ramalingam, Suresh S, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A, Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A, Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D, Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R, Reck, Martin

“…In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1)…”
Get more information

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial by Kim, Dong-Wan, Tiseo, Marcello, Ahn, Myung-Ju, Reckamp, Karen L, Hansen, Karin Holmskov, Kim, Sang-We, Huber, Rudolf M, West, Howard L, Groen, Harry J M, Hochmair, Maximilian J, Leighl, Natasha B, Gettinger, Scott N, Langer, Corey J, Paz-Ares Rodríguez, Luis G, Smit, Egbert F, Kim, Edward S, Reichmann, William, Haluska, Frank G, Kerstein, David, Camidge, D Ross

“…Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC) eventually…”
Get full text

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study by Gainor, Justin F, Curigliano, Giuseppe, Kim, Dong-Wan, Lee, Dae Ho, Besse, Benjamin, Baik, Christina S, Doebele, Robert C, Cassier, Philippe A, Lopes, Gilberto, Tan, Daniel S W, Garralda, Elena, Paz-Ares, Luis G, Cho, Byoung Chul, Gadgeel, Shirish M, Thomas, Michael, Liu, Stephen V, Taylor, Matthew H, Mansfield, Aaron S, Zhu, Viola W, Clifford, Corinne, Zhang, Hui, Palmer, Michael, Green, Jennifer, Turner, Christopher D, Subbiah, Vivek

“…Oncogenic alterations in RET have been identified in multiple tumour types, including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the…”
Get full text

Current Challenges in Cancer Treatment by Zugazagoitia, Jon, MD, PhD, Guedes, Cristiano, MD, Ponce, Santiago, MD, Ferrer, Irene, PhD, Molina-Pinelo, Sonia, PhD, Paz-Ares, Luis, MD, PhD

“…Abstract Purpose In this review, we highlight the current concepts and discuss some of the current challenges and future prospects in cancer therapy. We…”
Get full text

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227 by Brahmer, Julie R, Lee, Jong-Seok, Ciuleanu, Tudor-Eliade, Bernabe Caro, Reyes, Nishio, Makoto, Urban, Laszlo, Audigier-Valette, Clarisse, Lupinacci, Lorena, Sangha, Randeep, Pluzanski, Adam, Burgers, Jacobus, Mahave, Mauricio, Ahmed, Samreen, Schoenfeld, Adam J, Paz-Ares, Luis G, Reck, Martin, Borghaei, Hossein, O'Byrne, Kenneth J, Gupta, Ravi G, Bushong, Judith, Li, Li, Blum, Steven I, Eccles, Laura J, Ramalingam, Suresh S

“…We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with…”
Get full text

Targeted therapy for lung cancer: Beyond EGFR and ALK by Herrera‐Juárez, Mercedes, Serrano‐Gómez, Cristina, Bote‐de‐Cabo, Helena, Paz‐Ares, Luis

“…Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with…”
Get full text

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer by Mezquita, Laura, Auclin, Edouard, Ferrara, Roberto, Charrier, Melinda, Remon, Jordi, Planchard, David, Ponce, Santiago, Ares, Luis Paz, Leroy, Laura, Audigier-Valette, Clarisse, Felip, Enriqueta, Zerón-Medina, Jorge, Garrido, Pilar, Brosseau, Solenn, Zalcman, Gérard, Mazieres, Julien, Caramela, Caroline, Lahmar, Jihene, Adam, Julien, Chaput, Nathalie, Soria, Jean Charles, Besse, Benjamin

“…Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor…”
Get more information

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer by PAZ-ARES, Luis G, DE MARINIS, Filippo, CORRAL, Jesús, MELEMED, Symantha, JOHN, William, CHOUAKI, Nadia, ZIMMERMANN, Annamaria H, VISSEREN-GRUL, Carla, GRIDELLI, Cesare, DEDIU, Mircea, THOMAS, Michael, PUJOL, Jean-Louis, BIDOLI, Paolo, MOLINIER, Olivier, TARINI PRASAD SAHOO, LAACK, Eckart, RECK, Martin

“…In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62;…”
Get full text

Targeting EGFR in Lung Cancer: Current Standards and Developments by Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis

“…Lung cancer is the second most common malignant tumor and the leading cause of cancer death. Epidermal growth factor receptor (EGFR) -mutant non-small cell…”
Get full text

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study by Soria, Jean-Charles, Prof, Tan, Daniel S W, MD, Chiari, Rita, MD, Wu, Yi-Long, Prof, Paz-Ares, Luis, Prof, Wolf, Juergen, Prof, Geater, Sarayut L, MD, Orlov, Sergey, Prof, Cortinovis, Diego, MD, Yu, Chong-Jen, Prof, Hochmair, Maximillian, MD, Cortot, Alexis B, Prof, Tsai, Chun-Ming, Prof, Moro-Sibilot, Denis, MD, Campelo, Rosario G, MD, McCulloch, Tracey, MSc, Sen, Paramita, PhD, Dugan, Margaret, MD, Pantano, Serafino, PhD, Branle, Fabrice, MD, Massacesi, Cristian, MD, de Castro, Gilberto, MD

“…Summary Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase ( ALK )-rearranged non-small-cell lung cancer (NSCLC) is not…”
Get full text

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial by Huber, Rudolf M, Hansen, Karin H, Paz-Ares Rodríguez, Luis, West, Howard L, Reckamp, Karen L, Leighl, Natasha B, Tiseo, Marcello, Smit, Egbert F, Kim, Dong-Wan, Gettinger, Scott N, Hochmair, Maximilian J, Kim, Sang-We, Langer, Corey J, Ahn, Myung-Ju, Kim, Edward S, Kerstein, David, Groen, Harry J M, Camidge, D Ross

“…We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC. Patients were…”
Get more information

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial by Herbst, Roy S, Prof, Arkenau, Hendrik-Tobias, MD, Santana-Davila, Rafael, MD, Calvo, Emiliano, MD, Paz-Ares, Luis, Prof, Cassier, Philippe A, MD, Bendell, Johanna, MD, Penel, Nicolas, Prof, Krebs, Matthew G, MD, Martin-Liberal, Juan, MD, Isambert, Nicolas, MD, Soriano, Andres, MD, Wermke, Martin, MD, Cultrera, Jennifer, MD, Gao, Ling, PhD, Widau, Ryan C, PhD, Mi, Gu, PhD, Jin, Jin, PhD, Ferry, David, MD, Fuchs, Charles S, Prof, Petrylak, Daniel P, Prof, Chau, Ian, MD

“…SummaryBackgroundPre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances…”
Get full text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial by Rosell, Rafael, Dr, Carcereny, Enric, MD, Gervais, Radj, MD, Vergnenegre, Alain, Prof, Massuti, Bartomeu, MD, Felip, Enriqueta, MD, Palmero, Ramon, MD, Garcia-Gomez, Ramon, MD, Pallares, Cinta, MD, Sanchez, Jose Miguel, MD, Porta, Rut, MD, Cobo, Manuel, MD, Garrido, Pilar, MD, Longo, Flavia, MD, Moran, Teresa, MD, Insa, Amelia, MD, De Marinis, Filippo, MD, Corre, Romain, MD, Bover, Isabel, MD, Illiano, Alfonso, MD, Dansin, Eric, MD, de Castro, Javier, MD, Milella, Michele, MD, Reguart, Noemi, MD, Altavilla, Giuseppe, MD, Jimenez, Ulpiano, MD, Provencio, Mariano, MD, Moreno, Miguel Angel, MD, Terrasa, Josefa, MD, Muñoz-Langa, Jose, MD, Valdivia, Javier, MD, Isla, Dolores, MD, Domine, Manuel, MD, Molinier, Olivier, MD, Mazieres, Julien, Prof, Baize, Nathalie, MD, Garcia-Campelo, Rosario, MD, Robinet, Gilles, MD, Rodriguez-Abreu, Delvys, MD, Lopez-Vivanco, Guillermo, MD, Gebbia, Vittorio, MD, Ferrera-Delgado, Lioba, MD, Bombaron, Pierre, MD, Bernabe, Reyes, MD, Bearz, Alessandra, MD, Artal, Angel, MD, Cortesi, Enrico, MD, Rolfo, Christian, MD, Sanchez-Ronco, Maria, PhD, Drozdowskyj, Ana, PhD, Queralt, Cristina, PhD, de Aguirre, Itziar, PhD, Ramirez, Jose Luis, PhD, Sanchez, Jose Javier, Prof, Molina, Miguel Angel, PhD, Taron, Miquel, PhD, Paz-Ares, Luis, MD

“…Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian…”
Get full text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial by Thatcher, Nick, Prof, Hirsch, Fred R, Prof, Luft, Alexander V, MD, Szczesna, Aleksandra, MD, Ciuleanu, Tudor E, Prof, Dediu, Mircea, MD, Ramlau, Rodryg, Prof, Galiulin, Rinat K, MD, Bálint, Beatrix, MD, Losonczy, György, Prof, Kazarnowicz, Andrzej, MD, Park, Keunchil, MD, Schumann, Christian, Prof, Reck, Martin, MD, Depenbrock, Henrik, MD, Nanda, Shivani, MS, Kruljac-Letunic, Anamarija, PhD, Kurek, Raffael, MD, Paz-Ares, Luis, MD, Socinski, Mark A, Prof

“…Summary Background Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with…”
Get full text

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non-small Cell Lung Cancer by Yu, Helena A, Paz-Ares, Luis G, Yang, James Chih-Hsin, Lee, Ki Hyeong, Garrido, Pilar, Park, Keunchil, Kim, Joo-Hang, Lee, Dae Ho, Mao, Huzhang, Wijayawardana, Sameera R, Gao, Ling, Hozak, Rebecca R, Chao, Bo H, Planchard, David

“…We report the final analysis of JVDL (NCT02789345), which examined the combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the…”
Get full text